ABSTRACT
ABSTRACT Purpose: to assess the advancement in communicative intention and cognition in children with autism spectrum disorder after applying a personalized alternative communication method. Methods: patients had their communicative intention and cognition (Vineland-3) assessed before and after the intervention with 10 structured alternative communication sessions. The "Demystifying Alternative Communication" podcast was developed as supplementary material to this study. Student's t-test was used, setting the significance level at p < 0.05. Results: patients improved their communicative intention, with higher scores after the intervention, and no changes were found in relation to cognition. Conclusion: even though the patients' equivalent age was inferior to their real age in the communication subdomain assessment, they progressed in expressive communication, language, and writing.
RESUMO Objetivo: avaliar o avanço da intenção comunicativa e da cognição em crianças com Transtorno do Espectro Autista após a aplicação de metodologia personalizada de comunicação alternativa. Métodos: foram realizadas dez sessões estruturadas de comunicação alternativa e os pacientes foram avaliados antes e após a intervenção quanto a intenção comunicativa e cognição (Vineland-3). Como material suplementar deste trabalho, foi elaborado o podcast "Desmistificando a Comunicação Alternativa". Foi utilizado teste t-Student com o p <0,05 onsiderado significante. Resultados: os pacientes apresentaram melhoras quanto à intenção comunicativa, demonstrando maiores escores após a realização da intervenção. Conclusão: apesar de os pacientes apresentarem uma idade equivalente inferior à idade real na avaliação do subdomínio da comunicação, estes demonstraram avanços quanto às variáveis de comunicação expressiva, linguagem e escrita.
ABSTRACT
ABSTRACT Objective: To assess clinical outcomes of intolerant, relapsed or refractory patients who could not be treated with new tyrosine kinase inhibitors or experimental therapies. Methods: A retrospective cohort of 90 chronic myeloid leukemia patients in all phases of the disease treated with imatinib mesylate as their first TKI therapy, and with dasatinib or nilotinib as the next line of therapy. We evaluated clinical outcomes of these patients, with special focus on the group that needed more than two therapy lines. Results: Thirty-nine percent of patients were refractory or intolerant to imatinib. An 8-year overall survival rate of the patients who went through three or more lines of treatment was significantly lower, compared to those who were able to maintain imatinib as their first-line therapy (83% and 22%, respectively p < 0.01). Decreased overall survival was associated with advanced-phase disease (p < 0.01), failure to achieve major molecular response in first-line treatment (p < 0.01) and interruption of first-line treatment due to any reason (p = 0.023). Failure in achieving complete cytogenetic response and major molecular response and treatment interruption were associated with the progression to the third-line treatment. Conclusion: The critical outcome observed in relapsed, intolerant or refractory chronic phase CML patients reflects the unmet need for this group of patients without an alternative therapy, such as new drugs or experimental therapies in clinical trials. Broader access to newer treatment possibilities is a crucial asset to improve survival among CML patients, especially those refractory or intolerant to first-line therapies.
Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Child , Adolescent , Leukemia, Myelogenous, Chronic, BCR-ABL Positive , Survival Analysis , Imatinib Mesylate , DasatinibABSTRACT
Abstract Background Diffuse large B-cell lymphoma, among non-Hodgkin lymphomas, is one of the most frequent subtypes. Clinical laboratory data and post-treatment outcomes are scarce in the Brazilian population. Objective The main objective of this retrospective study was to assess the impact of tumor markers, including the Myeloid differentiation primary response 88 (MYD88) mutation. Method Eighty-three patients were included and treated with R-CHOP or R-CHOP-like regimens. Results Median age was 64-years old and 58% were female patients. The median follow-up was 42 months. The progression free survival (PFS) at this time was 63% and overall survival (OS), 66%. In the patients with tumors expressing Myc proto-oncogene protein (MYC) and B-cell lymphoma 2 (BCL2), assessed by immunohistochemistry (IHC), known as dual protein expressers, median post-progression survival was 31 (15-45) months. An increased proliferative index were associated with a high rate of progression (hazard ratio 2.31 [95% confidence interval [1.05-5.12]; p = 0.04). The cell of origin (COO), identified by IHC, was not able to predict PFS (p = 0.76). The MYD88 L265P mutation was present in 10.8% (9/83) of patients and did not show a prognostic correlation. Conclusion In conclusion, the MYD88 mutation, although an important tool for diagnosis and a possible target drug, presented at a low frequency and was not a prognostic marker in this population.
Subject(s)
Biomarkers, Tumor , Lymphoma, Large B-Cell, Diffuse , Myeloid Differentiation Factor 88 , MutationABSTRACT
ABSTRACT Chronic kidney disease (CKD) is a syndrome caused by the progressive reduction of renal function. This study aimed to systematically examine the effects of supplementation with probiotics in the treatment of CKD. Searches were carried out on databases MEDLINE (PubMed), SciELO, Cochrane, and Clinical Trials. Two independent reviewers selected the studies from which data was extracted. The search included papers written in English and Portuguese published in the 2012-2016 period describing randomized clinical trials. Eight of the 82 eligible articles met the inclusion criteria. Sample size ranged from 18 to 101 individuals with CKD. The duration of the included studies varied from four to 24 weeks. Most of the included articles reported positive effects in renal function and decreased levels of urea, blood urea nitrogen, ammonia, plasma p-cresol, p-cresyl sulfate, and indoxyl sulfate.
RESUMO A insuficiência renal crônica (IRC) é definida como uma síndrome causada pela redução progressiva da função renal. O objetivo deste trabalho foi revisar sistematicamente o efeito da suplementação probiótica no tratamento da IRC. Foi realizada uma busca nas bases de dados MEDLINE (PubMed), SciELO, Cochrane e Clinical Trials. Dois revisores independentes realizaram a seleção dos estudos e a extração de dados. A pesquisa incluiu estudos entre 2012-2016, do tipo estudo clínico randomizado, em inglês e em português. Dos 82 artigos elegíveis, 8 artigos preencheram os critérios de inclusão. O número amostral variou de 18 a 101 pacientes com IRC, com duração de 4 a 24 semanas de estudo. A maioria dos estudos relatados mostraram efeitos benéficos na redução das concentrações de ureia, nitrogênio ureico, amônia, p-cresol plasmático, sulfato de p-cresil e sulfato de indoxil, ou seja, os probióticos parecem estar relacionados à melhora da função de renal.